低危与高危患者经导管与外科主动脉瓣置换随机试验荟萃分析
该荟萃分析纳入8项随机对照试验共8698例患者,比较经导管主动脉瓣植入(TAVI)与外科主动脉瓣置换(SAVR)。低危患者中TAVI在1年时死亡及死亡或致残性卒中风险更低,但1年后主要结局无显著差异;高危患者主要结局均无显著差异。
要点
- 低危患者TAVI术后1年死亡风险低于SAVR(RR 0.67)。
- 低危患者TAVI术后1年死亡或致残性卒中复合风险更低(RR 0.68)。
- 高危患者TAVI与SAVR主要结局无显著差异。
核心结论
- 低危患者TAVI早期死亡风险降低,但后期随访无差异。
- 低危患者TAVI早期死亡或致残性卒中复合终点降低,后期无差异。
- 高危患者主要结局无显著差异。
研究设计与样本
- 随机对照试验的荟萃分析,纳入8项RCT共8698例患者。
- 采用实用性风险分类区分低危与高危患者。
- 主要终点为1年(早期)或1年后(后期)的死亡、卒中及死亡或致残性卒中复合终点。
- 采用随机效应模型进行荟萃分析。
主要发现
- 低危患者1年时TAVI较SAVR死亡风险更低(RR 0.67;95%CI 0.47-0.96,P=0.031)。
- 低危患者1年时TAVI较SAVR死亡或致残性卒中风险更低(RR 0.68;95%CI 0.50-0.92,P=0.014)。
- 低危患者1年时卒中无差异,1年后主要结局无显著差异。
- 高危患者主要结局无显著差异。
- TAVI后新发房颤、大出血和急性肾损伤更少,新起搏器、血管并发症和瓣周漏更多。
临床怎么用
- 低危患者选择TAVI可能获得早期死亡及致残性卒中获益。
- 高危患者TAVI与SAVR主要结局相当,决策需结合次要终点及事件时间性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Additional randomized clinical trial (RCT) data comparing transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) is available, including longer term follow-up. A meta-analysis comparing TAVI to SAVR was performed. A pragmatic risk classification was applied, partitioning lower-risk and higher-risk patients. METHODS AND RESULTS: The main endpoints were death, strokes, and the composite of death or disabling stroke, occurring at 1 year (early) or after 1 year (later). A random-effects meta-analysis was performed. Eight RCTs with 8698 patients were included. In lower-risk patients, at 1 year, the risk of death was lower after TAVI compared with SAVR [relative risk (RR) 0.67; 95% confidence interval (CI) 0.47 to 0.96, P = 0.031], as was death or disabling stroke (RR 0.68; 95% CI 0.50 to 0.92, P = 0.014). There were no differences in strokes. After 1 year, in lower-risk patients, there were no significant differences in all main outcomes. In higher-risk patients, there were no significant differences in main outcomes. New-onset atrial fibrillation, major bleeding, and acute kidney injury occurred less after TAVI; new pacemakers, vascular complications, and paravalvular leak occurred more after TAVI. CONCLUSION: In lower-risk patients, there was an early mortality reduction with TAVI, but no differences after later follow-up. There was also an early reduction in the composite of death or disabling stroke, with no difference at later follow-up. There were no significant differences for higher-risk patients. Informed therapy decisions may be more dependent on the temporality of events or secondary endpoints than the long-term occurrence of main clinical outcomes.
引用
- Ahmad Y, Howard JP, Arnold AD, et al. Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a meta-analysis of randomized trials. Eur Heart J. 2023. PMID: 36660821. doi:10.1093/eurheartj/ehac642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。